首页> 外文期刊>Cancer chemotherapy and pharmacology. >Population pharmacokinetic study of a test dose oral busulfan in Japanese adult patients undergoing hematopoietic stem cell transplantation.
【24h】

Population pharmacokinetic study of a test dose oral busulfan in Japanese adult patients undergoing hematopoietic stem cell transplantation.

机译:在日本成人进行造血干细胞移植的患者中,口服剂量白消安的群体药代动力学研究。

获取原文
获取原文并翻译 | 示例
           

摘要

PURPOSE: The aim of this study is to determine the population pharmacokinetics of oral busulfan in Japanese adults. METHODS: We previously underwent a clinical trial involving the dose adjustment of oral busulfan depending on the individual pharmacokinetics using a test dose in hematopoietic stem cell transplantation recipients. Seventy-one Japanese patients aged from 16 to 67 years were enrolled. After taking oral busulfan 0.5 mg/kg as a test dose, blood samples were collected at five time points from each patient. Busulfan concentrations were measured by high-performance liquid chromatography, and the individual parameters were estimated by using the nonlinear mixed effects model computer program. A one-compartment model with first-order absorption was sufficient to describe the concentration-time profile. RESULTS: The final pharmacokinetic parameter were the clearance (CL/F) = 0.153 L/h/kg, distribution volume (Vd/F) = 0.695 L/kg, and absorption rate constant (ka) = 2.39 h(-1). The inter-individual variabilities in CL/F, Vd/F and ka were 25.9, 26.2, and 111.8%, respectively, and the residual variability was 12.1% as the coefficient of variation. CONCLUSION: We developed a population pharmacokinetic model of oral busulfan in Japanese adults. The final population model was implemented into the program excel, leading to an easy and proper therapeutic monitoring of oral BU by using small number of samples.
机译:目的:本研究的目的是确定日本成年人口服白消安的总体药代动力学。方法:我们先前进行了一项临床试验,涉及在造血干细胞移植受者中根据测试药剂量,根据个体药代动力学调整口服白消安的剂量。入选了21名16至67岁的日本患者。口服0.5mg / kg的白消安作为测试剂量后,在五个时间点从每位患者收集血液样品。通过高效液相色谱法测定白消安的浓度,并使用非线性混合效应模型计算机程序估算各个参数。具有一阶吸收的单室模型足以描述浓度-时间曲线。结果:最终药代动力学参数是清除率(CL / F)= 0.153 L / h / kg,分布体积(Vd / F)= 0.695 L / kg,吸收速率常数(ka)= 2.39 h(-1)。 CL / F,Vd / F和ka的个体间变异分别为25.9、26.2和111.8%,而作为变异系数的剩余变异性为12.1%。结论:我们在日本成年人体内建立了口服白消安的群体药代动力学模型。最终的人口模型已在excel程序中实施,从而通过使用少量样本即可轻松,正确地对口腔BU进行治疗性监测。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号